Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; shampoo for dogs, cats, and horses under the Alosera trademark; and pet oral care solutions under the StrixNB and bluestem trademarks. The company was founded in 2001 and is based in Winnipeg, Canada.
Industry, Sector and Symbol
Stock Exchange CVE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolCVE:KNE
CUSIPN/A
Phone+1-204-4531301
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,545.33%
Return on Equity-172.74%
Return on Assets-121.67%
Miscellaneous
EmployeesN/A
Outstanding Shares80,114,000
Market CapC$6.01
Kane Biotech (CVE:KNE) Frequently Asked Questions
What is Kane Biotech's stock symbol?
Kane Biotech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KNE."
How were Kane Biotech's earnings last quarter?
Kane Biotech Inc (CVE:KNE) posted its quarterly earnings data on Thursday, May, 17th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.09 million for the quarter. Kane Biotech had a negative return on equity of 172.74% and a negative net margin of 1,545.33%. View Kane Biotech's Earnings History.
When is Kane Biotech's next earnings date?
What is the consensus analysts' recommendation for Kane Biotech?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kane Biotech in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Kane Biotech's key competitors?
Some companies that are related to Kane Biotech include Liberty Biopharma (LTY), Fusion Antibodies (FAB), Burcon NutraScience (BU), Ampliphi Biosciences (APHB), Synairgen (SNG), Hvivo (HVO), Quest PharmaTech (QPT), Collagen Solutions (COS), Hemostemix (HEM), Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP), CorMedix (CRMD), Physiomics (PYC), ValiRx (VAL), Vernalis (VER) and Midatech Pharma (MTPH).
Who are Kane Biotech's key executives?
Kane Biotech's management team includes the folowing people:
- Mr. Mark Ahrens-Townsend, CEO, Pres & Director
- Mr. Ray Dupuis, Chief Financial Officer
- Mr. L. Michael Coutts, Director of Bus. Devel.
- Mr. Grant Humphrey, VP of Sales
- Dr. Tony Romeo, Chief Scientific Advisor and Member of Scientific Advisory Board
Has Kane Biotech been receiving favorable news coverage?
News coverage about KNE stock has trended somewhat positive on Friday, according to Accern. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kane Biotech earned a coverage optimism score of 0.15 on Accern's scale. They also gave news coverage about the company an impact score of 45.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Kane Biotech?
Shares of KNE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Kane Biotech's stock price today?
One share of KNE stock can currently be purchased for approximately C$0.06.
How big of a company is Kane Biotech?
Kane Biotech has a market capitalization of C$6.01 million.
How can I contact Kane Biotech?
Kane Biotech's mailing address is 162-196 Innovation Dr, WINNIPEG, MB R3T 6C5, Canada. The company can be reached via phone at +1-204-4531301.
MarketBeat Community Rating for Kane Biotech (CVE KNE)
MarketBeat's community ratings are surveys of what our community members think about Kane Biotech and other stocks. Vote "Outperform" if you believe KNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
